Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Label indication ALPHAGAN P (brimonidine tartrate ophthalmic solution) 0.1% or 0.15% is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. ALPHAGAN P is an alpha adrenergic agonist indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. ( 1 ) FDA label
Also known as Brimonidine Tartrate Ophthalmic Solution 0.2%, Brimonidine 0.2%, Brimonidine ophthalmic solution 0.1%, Brimonidine 0.1%, Brimonidine 0.2% ophthalmic solution
Brimonidine · 8 trials · 4 indications
BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters). The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly indicates that vision has improved. The percentage of patients with at least a 15-letter increase in BCVA in the study eye is reported.
Visual field improvement in the study eye is determined using the Humphrey Field Analyzer (HFA 24-2) full threshold test and clinical expertise. The Humphrey Field Analyzer is a machine that helps to map the field (peripheral) of vision. An improvement is an increase in the field of vision. The percentage of patients with a visual field improvement in the study eye is reported.
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Brimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic Solution |
| 2 | ACTIVE_COMPARATOR | Concurrent Brimonidine 0.2% and 0.5% Timolol |
| 400 ug Brimonidine Implant | EXPERIMENTAL | 400 ug Brimonidine Tartrate Posterior Segment Drug Delivery system on Day 1 in the study eye. |
| 200 ug Brimonidine Implant | EXPERIMENTAL | 200 ug Brimonidine Tartrate Posterior Segment Drug Delivery system on Day 1 in the study eye. |
| Sham (no implant) | SHAM_COMPARATOR | Sham Posterior Segment Drug Delivery system on Day 1 in the study eye. |
| Name | Type | Description |
|---|---|---|
| Brimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic Solution | DRUG | Brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution 1 drop instilled in each eye two times daily (morning and evening) |
| Concurrent brimonidine 0.2% and 0.5% timolol | DRUG | Brimonidine 0.2%, 1 drop instilled in each eye three times daily (morning, afternoon, and evening) and timolol 0.5% timolol, 1 drop instilled in each eye twice daily (morning and evening) and vehicle of brimonidine combination ophthalmic solution 1 drop instilled in each eye (morning, afternoon and/or evening) |
| brimonidine | DRUG | - |
| Brimonidine ophthalmic solution 0.1% | DRUG | 1 drop instilled in each eye 3 times daily (08:00, 14:00, 20:00) |
| Brimonidine ophthalmic solution 0.2% | DRUG | 1 drop instilled in each eye 3 times daily (08:00, 14:00, 20:00) |
| brimonidine/timolol fixed combination | DRUG | - |
| 400 ug Brimonidine Implant | DRUG | 400 ug Brimonidine Tartrate Posterior Segment Drug Delivery system on Day 1 in the study eye. |
| 200 ug Brimonidine Implant | DRUG | 200 ug Brimonidine Tartrate Posterior Segment Drug Delivery system on Day 1 in the study eye. |
| Sham (no implant) | OTHER | Sham Posterior Segment Drug Delivery system on Day 1 in the study eye. |
Inclusion Criteria: * Diagnosis of ocular hypertension or glaucoma * Patient requires IOP-lowering therapy in both eyes Exclusion Criteria: * Uncontrolled medical conditions * Contraindication to β-adrenoceptor antagonist therapy or brimonidine therapy
Top 5 of 7 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 6 | PHASE3 | Gen 2 Travoprost Intracameral, Travoprost |
| SpyGlass Pharma, Inc. | SGP | 5 | PHASE3 | Bimatoprost System, BIM-DRS |
| AbbVie, Inc. | ABBV | 2 | PHASE3 | AGN-193408 |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 1 | PHASE3 | Bimatoprost ophthalmic solution |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE1 | REGN22530 |
Brimonidine is used in ophthalmology for glaucoma, open-angle glaucoma, and ocular hypertension, and it has also been studied in rhegmatogenous macula-off retinal detachment. It is a small molecule developed by AbbVie Inc. (ticker ABBV) and is in Phase 3 development.
Brimonidine targets the alpha-2 adrenergic receptors ADRA2A, ADRA2C, and ADRA2B, acting as an agonist at these receptors. This receptor activity underlies its use in ophthalmic conditions such as glaucoma and ocular hypertension.
Brimonidine is developed by AbbVie Inc., which trades under the ticker ABBV. AbbVie is the company associated with the brimonidine programs, including the ophthalmic solution and fixed combination formulations.
Brimonidine is in Phase 3 development. It is an investigational small molecule, and the clinical program includes completed Phase 2 and Phase 3 trials. It has been studied across glaucoma, ocular hypertension, and retinal detachment indications.
Brimonidine has been evaluated in several completed trials, including NCT00652483 and NCT00651612, both Phase 3 studies in glaucoma or ocular hypertension, and Phase 2 trials NCT00972374 in retinal detachment and NCT00693485 in open-angle glaucoma. These trials enrolled a combined total of 1,244 participants.
Yes, Brimonidine is also known as Brimonidine Tartrate Ophthalmic Solution 0.2%, Brimonidine 0.2%, Brimonidine ophthalmic solution 0.1%, Brimonidine 0.1%, the 400 ug Brimonidine Implant, and the Brimonidine 0.2%/Timolol 0.5% fixed combination ophthalmic solution. These names refer to the same active agent in different formulations.